NFKB1 and inflammatory bowel disease: Although the mechanism by which PPARγ acts on the pathogenesis of IBD has not been clarified, it may involve cyclooxygenase-2 (COX2) and NF-κB modulation, resulting in inhibition of monocyte inflammatory cytokines and reactive oxygen species (ROS).